Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 5/20 | 0.61 |
| ▸ | BRAF | P15056 | 7/20 | 0.52 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5205278 | 0.85 | FYN (0.53) | FYNBRAFCSF1RGAARECQL | |
| SCHEMBL5210710 | 0.84 | CLK4 (0.53) | FYNBRAFCSF1RCXCL12 | |
| SCHEMBL5204384 | 0.80 | PIK3CG (0.60) | FYNBRAFCSF1RGAAMAPK1 | |
| SCHEMBL12065316 | 0.79 | FYN (0.57) | FYNBRAFCSF1RGAARECQL | |
| SCHEMBL12056818 | 0.77 | FYN (0.55) | FYNBRAFCSF1RMAPK1PIK3CA | |
| SCHEMBL12056775 | 0.77 | FYN (0.55) | FYNBRAFCSF1RMAPK1PIK3CA | |
| SCHEMBL18613216 | 0.77 | FYN (1.00) | FYNBRAFGAARECQLGFER | |
| SCHEMBL5208271 | 0.75 | FYN (0.67) | FYNBRAFCSF1RGAAPIM3 | |
| SCHEMBL5934776 | 0.75 | FYN (0.67) | FYNBRAFCSF1RGAAPIM3 | |
| SCHEMBL14394170 | 0.74 | FYN (0.51) | FYNBRAFCSF1RGAARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513821-B1 | PROTEIN KINASE INHIBITORS | CYTOPIA PTY LTD (AU) | 2007-10-31 | — | — | EP | disclosed |
| US-7122550-B2 | Protein kinase inhibitors | CYTOPIA PTY LTD (AU) | 2006-10-17 | — | — | US | disclosed |
| US-20060148824-A1 | Protein kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2006-07-06 | — | — | US | disclosed |
| US-20040235862-A1 | For therapy of atopy, a cell mediated hypersensitivity, a rheumatic disease, an autoimmune disease, a viral disease, and a cancer | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235862-A1 | For therapy of atopy, a cell mediated hypersensitivity, a rheumatic disease, an autoimmune disease, a viral disease, and a cancer | LCK, IRAK1, MAP2K5 | FYN 498/4885BRAF 89/4885CALM1 1062/4885 |
| US-20060148824-A1 | Protein kinase inhibitors | MAP3K20, MAP4K2, MAP3K1 | FYN 359/4885BRAF 49/4885CALM1 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.